You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm said that the proceeds will be used to complete the development of the Cue Health Monitoring System and Cue Test Cartridges.
The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.
The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.
Researchers have developed a smartphone-powered device that can identify DNA in various sample types, New Scientist reports.
The platform's portability and internet connectivity could enable it to locate and track the distribution of disease in real time, its developers said.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
The firm's whole-genome amplification chemistry may help researchers better understand cancer heterogeneity, even between cells.
The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.
Functional enhancers can accompany oncogenes on the circularized extrachromosomal amplicons found in glioma and other tumors, enhancing cancer growth.
UK researchers said they are developing a commercial test that could enable sensitive detection of tuberculosis DNA in blood and provide an option to broaden screening.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.